

National Multiple Sclerosis Society

MS Outcomes Assessment Consortium Overview

Tim Coetzee, PhD

Chief Advocacy, Services & Science Officer National MS Society Clinical Outcome Measures for Multiple Sclerosis Why do we struggle with this?

"Precise measure of the clinical manifestations of MS is difficult because neurological impairment and disability vary in different patients and over time, and neurological function is inherently difficulty to quantify."

Rudick, Antel, Confavreux, et al. Annals of Neurology, 1997



Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects

Jeffrey A Cohen, Stephen C Reingold, Chris H Polman, Jerry S Wolinsky, for the International Advisory Committee on Clinical Trials in Multiple Sclerosis

Lancet Neurology, 2012

"For the study of MS to advance, more informative disability measures are needed."

"To attain these goals will require a collaborative approach that involves academic experts, regulators, industry representatives, and funding agencies."



Attributes of a new MS COA

- Measures the impact of an intervention on the disability due to MS and is qualified for use in registration trials
- Acceptable to patient, and be:
 - Multidimensional to reflect the principal ways that MS affects an individual
 - Highly reliable and valid including meaningful to the patient
 - Sensitive to change over time to permit demonstration of a therapeutic effect
 - Practical and cost-effective



Goals of the MSOAC Consortium

- Create MS therapeutic area data standards, leveraging efforts already underway
- Remap legacy MS clinical trial data into common MS therapeutic area data standards.
- Create an online MS database of aggregated, standardized clinical data, and make this resource publicly available to qualified researchers
- Create scientific consensus on the optimal components for inclusion in a modified MS Functional Composite (MSFC)
- Advance a new clinical outcome assessment drug development tool based on the MSFC to the FDA and EMA for regulatory qualification



Deliverables

A CDISC data standard for MS

 CDISC is a standards setting organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata

- A database of pooled, de-identified clinical trial data mapped to the CDISC standard
- A new methodology to measure performance as a primary or secondary endpoint in MS clinical trials. The composite measure will be submitted for qualification by the EMA and FDA



MSOAC Engages all Stakeholders

• MSOAC Leadership

• Lynn Hudson (C-Path), Nicholas LaRocca (NMSS), Richard Rudick (Cleveland Clinic)

10 pharmaceutical companies


 Abbvie, Acorda, Biogen Idec, Bristol-Myers Squibb, Glaxo Smith Kline, EMD Serono, Novartis, Genzyme/Sanofi, Roche, Teva

Patient Advocacy Organizations

- NMSS, AISM, MS Society of UK, MS Society of Canada, Alberta MS Research Foundation, CMSC
- Regulators and Government Funding Agencies
- 30 Academic Investigators



MSOAC Structure






Data Sets Collected

Study	CT.gov #	n	Туре	EDSS	FSS	T25FW	9HPT	PASAT	SDMT	LCVA	SF-36	BDI-II
ADVANCE	NCT00906399	1512	RRMS	\checkmark	SF-12	\checkmark						
AFFIRM	NCT00027300	939	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	\checkmark	No
CARE-MS 1	NCT00530348	563	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	\checkmark	No
CARE-MS 2	NCT00548405	798	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	\checkmark	No
CombiRx	NCT00211887	1008	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	\checkmark	No
FREEDOMS	NCT00289978	1272	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	No	No	No
FREEDOMS II	NCT00355134	1083	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	No	No
IMPACT	N/A	434	SPMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	No	\checkmark	\checkmark
MAESTRO	NCT00869726	610	SPMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	No	\checkmark	No
PROMISE	N/A	943	PPMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	No	\checkmark	No
SENTINEL	NCT00030966	1196	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	\checkmark	\checkmark
STRATA	NCT00297232	1094	RRMS	\checkmark	\checkmark	No	No	No	\checkmark	No	No	BDI-FS
TEMSO	NCT00134563	1086	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	No	\checkmark	No
TRANSFORMS	NCT00340834	1292	RRMS	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	No	\checkmark	No	No



Timeline





Outcomes

- International collaborative effort that elevated importance of new MS outcomes
- CDISC standards for MS
- Pooled clinical trial data available to the MS community
- Qualification package of MS COA submitted to EMA
 - Agency declined to qualify as stand-alone measure. Ok when used with EDSS
- Qualification package to FDA for SDMT

Anticipate decision in 2024



Considerations

- Clear rationale
- Investment (Society funding ~\$3 million plus in kind from data contributors)
- Partner with regulatory expertise and connection to FDA/EMA
- Patience
- Adaptability

